Building on evidence from the phase 3 COVE trial, the authors report the long-term safety and effectiveness of primary vaccination and boosting with mRNA-1273 against COVID-19, including during emergent variant waves.
- Lindsey R. Baden
- Hana M. El Sahly
- Jacqueline M. Miller
